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Abstract
Background: Mouse studies have recently compared the age-onset patterns of cancer between
different genotypes. Genes associated with earlier onset are tentatively assigned a causal role in
carcinogenesis. These standard analyses ignore the great amount of information about kinetics
contained in age-onset curves. We present a method for analyzing kinetics that measures
quantitatively the causal role of candidate genes in cancer progression. We use our method to
demonstrate a clear association between somatic mutation rates of different DNA mismatch repair
(MMR) genotypes and the kinetics of cancer progression.
Methods: Most experimental studies report age-onset curves as the fraction diagnosed with
tumors at each age for each group. We use such data to estimate smoothed survival curves, then
measure incidence rates at each age by the slope of the fitted curve divided by the fraction of mice
that remain undiagnosed for tumors at that age. With the estimated incidence curves, we compare
between different genotypes the median age of cancer onset and the acceleration of cancer, which
is the rate of increase in incidence with age.
Results: The direction of change in somatic mutation rate between MMR genotypes predicts the
direction of change in the acceleration of cancer onset in all 7 cases (p ˜ 0.008), with the same result
for the association between mutation rate and the median age of onset.
Conclusion:  Many animal experiments compare qualitatively the onset curves for different
genotypes. If such experiments were designed to analyze kinetics, the research could move to the
next stage in which the mechanistic consequences of particular genetic pathways are related to the
dynamics of carcinogenesis. The data we analyzed here were not collected to test mechanistic and
quantitative hypotheses about kinetics. Even so, a simple reanalysis revealed significant insights
about how DNA repair genotypes affect separately the age of onset and the acceleration of cancer.
Our method of comparing genotypes provides good statistical tests even with small samples for
each genotype.
Background
Experimental studies of cancer genetics often compare a
control population of mice to an experimental popula-
tion in which a candidate cancer gene has been altered.
The experiment measures the age of tumor onset in partic-
ular tissues for the control and experimental groups.
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GI tumor kinetics for three MMR knockout mouse genotypes Figure 1
GI tumor kinetics for three MMR knockout mouse genotypes. For each genotype, both alleles at each locus were 
knocked out. a Kaplan-Meier estimate [2] at each age of the fraction of mice that have not yet developed GI tumors among the 
population of mice that remain at risk. b Smoothed curve fit to the estimated survival curve in a using the smooth.spline func-
tion of the R computing language [2] with the smoothing parameter set to 0.5. c Incidence of GI tumors on log-log scales. d 
The acceleration of tumor onset calculated from the slope of the lines in c. Each column of plots corresponds to one of the 
three methods for dealing with the 7 observed GI carcinomas; we explained the different methods in the text. In our calcula-
tions, we truncated the curves at survival fractions below 0.2 because the errors in incidence estimates rise rapidly at low lev-
els of survival. The spreadsheet included in the supplemental materials provides a full listing of the data used to generate 
Figures 1 and 2.
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If the age-onset curve for the experimental group is shifted
to an earlier age relative to the control group, then the
altered gene plays a role in the rate of cancer progression.
The typical analysis often stops at a qualitative conclu-
sion: either the gene does or does not play a role.
We present a method to extract quantitative information
from such studies – information about the kinetics of pro-
gression. For example, does the altered gene simply shift
onset to an earlier age or does it increase the rate at which
incidence increases with age? Among a set of altered gen-
otypes, how does abrogating different functions affect the
age of onset and the rate of increase in incidence?
The way to measure causality of genes in cancer is to meas-
ure the quantitative effects of genes on the age-onset pat-
terns of disease. Thus, methods to extract and analyze
kinetic information from experimental studies provide an
important step in the development of the subject.
Here, we develop the methods for quantitative analysis
and apply those methods to experimental data of age-
onset patterns for different DNA mismatch repair (MMR)
genotypes. The MMR genotypes have different rates of
somatic mutation, so our kinetic analysis provides infor-
mation about how somatic mutation rates affect quantita-
tive aspects of cancer progression.
Methods
Data collection
We analyze data originally described by Chen et al. [1].
We supplemented the data with additional observations
collected by the same methods and obtained following
publication of [1]. When a mouse became morbid, it was
sacrificed and surveyed; all malignancies were confirmed
by histopathology. Each mouse was scored as positive or
negative for lymphoma, GI adenoma, or GI carcinoma. A
single mouse could be positive for both lymphoma and a
GI tumor; however, GI adenomas and carcinomas are
mutually exclusive.
Over all 135 mice in our data, 91 were diagnosed with
lymphoma. Consistent with other studies of MMR defi-
cient mice, the great majority of GI tumors were adeno-
mas: 62 had GI adenomas and 7 had GI carcinomas.
Below, we discuss the problem of analyzing the different
progression stages represented by GI adenomas and carci-
nomas. Of the 135 mice, 6 died of unknown cause and so
were scored negatively for both lymphomas and GI can-
cers. We include those 6 mice in our analyses because
their ages of death contribute to the changing base popu-
lation of mice at risk at different ages.
By using observed morbidity to measure age of onset,
there is a time lag between the final molecular progression
event that leads to tumor growth and the observation of
morbidity. We tested how time lags affected our quantita-
tive methods by reanalyzing our data under the assump-
tion that the age of onset is one or two months earlier than
the recorded age of morbidity. Time shifts had only small
quantitative effects on our estimates of kinetics, and the
lags did not affect any comparisons or statistical evalua-
tions based on the aggregate of the various comparisons
(results for time lag adjustments not shown). The insensi-
tivity of our results to the magnitude of time lags arises
from the fact that we measure kinetics relative to logarith-
Lymphoma kinetics for four MMR knockout mouse geno- types Figure 2
Lymphoma kinetics for four MMR knockout mouse 
genotypes. Lymphoma data plotted with the same style as 
the plots in Figure 1. The columns show the different meth-
ods for dealing with the 7 mice who had GI carcinomas, as 
explained in the text. Methods 2 and 3 are equivalent for 
analysis of the lymphoma data.
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mic scaling of time, and potential lags cause only small
distortions along the time dimension.
See Additional file 1: figure1Data.xls for the data analyzed
in this paper.
Quantitative analysis
Figure 1a shows age-onset data for gastrointestinal (GI)
tumors for different MMR genotypes. This plot presents
the Kaplan-Meier estimate [2] at each age of the fraction
of mice that have not yet developed GI tumors among the
population of mice that remain at risk. A mouse diag-
nosed with lymphoma but no GI tumor is scored as
removed from the population at the age of diagnosis. This
type of Kaplan-Meier curve is often referred to as a survival
curve, S(t), because it provides an estimate of the expected
fraction of mice that would be diagnosed with GI cancer
at each age, t, if GI cancer were the only cause of morbid-
ity. We used an analogous method for the lymphoma data
in Figure 2a, treating those mice with GI tumors but no
lymphoma as removed from the population at the age of
diagnosis.
Figure 1b shows a smoothed survival curve fit to the Kap-
lan-Meier plot. From the survival curve, S(t), in Figure 1b,
we estimate for each genotype the incidence rate, or prob-
ability of GI cancer per month at age t, as I(t) = -(dS(t)/
dt)/S(t), which is proportional to the estimated number
of new cases per unit time divided by the number of undi-
agnosed individuals at that time.
The classical way of quantitatively evaluating incidence
data comes from the multistage theory of carcinogenesis
[3]. According to that theory, if there are n stages in the
development of cancer, and the transition rate between
stages is u, then I(t) ≈ untn-1/n-1!, where u is often related
to the rate of somatic mutation. When testing specific
mechanistic hypotheses, one can use other forms of the
incidence function that account for additional processes,
such as clonal expansion of precancerous lesions [4].
It is useful to analyze the logarithm of incidence versus the
logarithm of age. In the classical form, taking the loga-
rithm of both sides yields log(I(t)) ˜ log(un/n-1!) + (n-
1)log(t). Similar expressions would be obtained by using
other theoretical predictions for incidence.
Our analysis does not depend on any particular mathe-
matical theory of progression and incidence. Instead, we
formulate comparative hypotheses about the expected
direction of change in cancer progression kinetics when
comparing different genotypes. Our simple qualitative
hypotheses do not depend on detailed assumptions about
progression dynamics.
Results
Figure 1c shows plots of log(I(t)) versus log(t), where we
used the smoothed curves in Figure 1b to calculate I(t),
and then fit straight lines through the values of I(t) on a
log-log scale. We fit straight lines because the data provide
enough information to get a good estimate of the slope,
but not enough information to provide a good estimate of
the curvature of the log-log plots at different ages.
The incidence, I(t), is the rate of cancer at each age. It is
often useful to study how cancer incidence changes with
age. Changes in the incidence rate can be measured by the
acceleration, which is the derivative (slope) of the inci-
dence (rate) curve; acceleration is simply a measure of
how fast the incidence rate, I(t), changes with age. We
measure the log-log acceleration of cancer with age, which
is dlog(I(t))/dlog(t) [5,6]. Figure 1d shows the log-log
accelerations for each genotype.
To estimate survival curves, we had to decide how to treat
the seven mice with GI carcinomas (see Methods and the
full data set in the supplemental information). We used
three alternative methods: (1) delete the seven mice from
all analyses for both GI cancers and lymphoma; (2) for GI
cancers, treat the GI carcinomas as a different disease and
score those mice as removed from the population at the
age of diagnosis, and score lymphomas as present or
absent in the normal way for those seven mice; and (3)
score the GI carcinomas as adenomas but set the age of
onset one month earlier than observed because carcino-
mas represent a later stage in progression than do adeno-
mas, and score lymphomas as present or absent in the
normal way for those seven mice.
Figure 1 shows our analysis of GI data for the three differ-
ent methods of treating GI carcinomas. Figure 2 shows our
analysis of lymphoma data for the three methods: note
that methods 2 and 3 are equivalent for lymphomas. The
qualitative patterns remain unchanged between methods,
and the quantitative changes are small.
Discussion
Multistage theory for the kinetics of carcinogenesis makes
three qualitative predictions. First, the fewer the number
of steps in progression that must be passed, the lower the
acceleration of cancer with age. In mouse experiments, the
theory predicts that abrogation of tumor suppressor func-
tions or introduction of oncogenes reduces the accelera-
tion. Second, small to moderate increases in the mutation
rate, u, cause greater cancer incidence at earlier ages but do
not affect the acceleration. Third, large increases in u can
cause such rapid transitions between stages that certain
mutations required for carcinogenesis may no longer
limit the rate of tumor formation. If some transitions no
longer limit the kinetics of carcinogenesis, the number ofBMC Cancer 2005, 5:163 http://www.biomedcentral.com/1471-2407/5/163
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rate-limiting steps decreases, and the acceleration
declines.
MMR genotypes affect both mutation rate and apoptosis
in response to DNA damage. Apoptosis has tumor sup-
pressor function and may often be a rate-limiting step in
carcinogenesis. Previous work [1,7] showed that the
mutation rates for the four knockout genotypes can be
ordered as Mlh3 < Pms2 < Mlh1 ˜ Mlh3Pms2, and the
decreased apoptosis in response to DNA damage of the
four genotypes can be ordered as Mlh3 ˜ Pms2 < Mlh1 ˜
Mlh3Pms2.
Table 1 shows that differences in mutation rate predict the
direction of change in acceleration and median age of
onset. Note that it is possible to have later age of onset and
lower acceleration, so acceleration and age of onset are
two independent dimensions of the kinetics. The direc-
tion of change in mutation rate predicts the direction of
change in the acceleration in all 7 cases (p ˜ 0.008), with
the same result for the association between mutation rate
and age of onset. Differences in anti-apoptotic effects (not
shown) also predict the direction of change in accelera-
tion and age of onset.
Conclusion
We presented a method to test causal hypotheses about
cancer progression kinetics. Our method is based on the
concept that a genotype has a causal influence on carcino-
genesis only to the extent that the genotype affects the age-
specific incidence curves of cancer.
Limited sample sizes present the greatest problem in stud-
ies that estimate age-specific incidence for particular gen-
otypes. To get around this limitation, we formulated our
hypotheses as predictions about the direction of change in
comparisons between genotypes. For example, we pre-
dicted that acceleration would decline in a sample with
relatively stronger defects in mismatch repair when com-
pared against a sample with relatively weaker defects in
mismatch repair.
By formulating each key prediction in a comparative way,
mouse data with small sample sizes can be used. Each
comparison provides a single binary outcome that repre-
sents either a success or failure of the theory to predict the
direction of change in some attribute of incidence kinet-
ics. The binary outcomes can be aggregated to form a non-
parametric test based on the binomial distribution. This
allows our approach to be applied to small samples of
mice in each genotype. The effective sample size comes
from the number of comparisons.
Over the past few years, vast resources have been
expended on animal experiments that compare survival
curves for different genotypes. If these sorts of experi-
ments were designed and analyzed with kinetics in mind,
the research could move to the next stage in which the
mechanistic consequences of particular genetic pathways
are related to the dynamics of carcinogenesis. The data we
analyzed here were not collected to test mechanistic and
quantitative hypotheses about kinetics. A simple reanaly-
sis revealed significant insights about how DNA repair
genotypes affect separately the age of onset and the accel-
eration of cancer.
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Table 1: Comparison of tumor kinetics for four different MMR 
genotypes. The '+' and '-' symbols show the direction of change 
for each comparison. In each comparison, the genotype with the 
higher mutation rate had a lower acceleration and median age of 
onset.
Comparison Type Acceleration Age Mutation
Mlh3 v Mlh3Pms2 GI tumor + + -
Mlh3 v Mlh1 GI tumor + + -
Mlh3 v Mlh3Pms2 Lymphoma + + -
Mlh3 v Mlh1 Lymphoma + + -
Pms2 v Mlh3Pms2 Lymphoma + + -
Pms2 v Mlh1 Lymphoma + + -
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